Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT03756103

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03756103
Other papers using this trial's data
  • A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension Hypertension research : official journal of the Japanese Society of Hypertension, 2024-07 DOI, PubMed 38632457, PMC11224011 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03756103. Randomized; double masking; primary purpose treatment. Start 2019-01-11 (actual); primary completion 2020-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
Condition
Hypertension,Essential
Intervention (Drug)
SPH3127 tablet Dose 1
Intervention (Drug)
SPH3127 tablet Dose 2
Intervention (Drug)
SPH3127 tablet Dose 3
Intervention (Drug)
SPH3127 tablet Placebo
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd (class: industry)
Collaborator
R&G Pharma Studies Co.,Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03756103
Content hash
5400958f55f9ebcebe981c599396f1ebef44926a46141a6826b85efe9d8a8436